title: What are the rules when treatment with 6-MP/AZA is started?
authors.affiliation: Lenox Hill Hospital, New York University School of Medicine, New York, USA.
authors.forename: Burton I
authors.initials: BI
authors.lastname: Korelitz
mesh_terms: D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D001379:Azathioprine